Samsung Biologics Sees Biosimilars As One Of Three Key Pillars
Follows Deal To Take Full Ownership Of Samsung Bioepis From Biogen
Samsung Biologics has reiterated the importance of biosimilars to its business in the wake of its move to buy out partner Biogen’s stake in their Samsung Bioepis biosimilars joint venture.
